San Diego-based mostly Viking Therapeutics marked itself as a serious competitor in the weight loss drug sector in February following revealing promising facts from a mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the company unveiled